



Amgen has proven expertise with a diverse range of medicines—and seeks opportunities in all modalities that match our strategy and capabilities (proteins, antibodies, small molecules and peptides).

ONCOLOGY/HEMATOLOGY

Oncology targeted therapies

Growth regulation

Signal transduction

Apoptosis/survival pathways

Cell cycle regulation

DNA damage/checkpoint

Oncology – novel antibodies and cell surface targets

Hematology

Neutropenia

Iron metabolism

Thrombocytopenia

Myelodysplastic syndrome

Myeloproliferative disorders

Supportive care

Cancer cachexia

Neuropathy

Cancer pain

INFLAMMATION

Rheumatoid arthritis

Psoriasis

Asthma

Multiple sclerosis

Systemic lupus erythematosus

Inflammatory bowel disease

Osteoarthritis

NEUROSCIENCE

Neurodegenerative diseases

Pain

Multiple sclerosis

Cognitive disorders

Migraine

BONE LOSS

Postmenopausal osteoporosis

Treatment-related bone loss

Bone metastasis

METABOLISM AND MUSCLE

Type 2 diabetes

Dyslipidemia

Muscle wasting/sarcopenia

NEPHROLOGY

Anemia

Disorders of calcium/phosphate metabolism

Hyperparathyroidism

Renal cachexia

Kidney transplant

Chronic allograft nephropathy

Diabetic nephropathy

DISCOVERY AND TECHNOLOGY

Drug discovery collaborations

Novel target ID/validation

Protein engineering and 2nd generation antibody platforms

Biomarker and patient stratification assays

Innovative chemical/peptide collections

Conjugation and drug delivery technologies

Imaging reagents and systems

Research tools

CARDIOVASCULAR

Heart failure

Cardioprotection

Atherosclerosis

Acute coronary syndromes